Exact Mass: 506.2781
Exact Mass Matches: 506.2781
Found 500 metabolites which its exact mass value is equals to given mass value 506.2781
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside]
4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside] is found in fruits. 4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside] is a constituent of Cydonia vulgaris (quince). Constituent of Cydonia vulgaris (quince). 4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside] is found in fruits.
(3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside]
(3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside] is found in tea. (3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside] is a constituent of leaves of Camellia sinensis var. sinensis (China tea). Constituent of leaves of Camellia sinensis variety sinensis (China tea). (3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside] is found in tea.
(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide
(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is found in fruits. (5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). (5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is found in fruits.
Ixabepilone
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. [Wikipedia] Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone lactam modification that
Bemcentinib
Abemaciclib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
Chromogenic Substrate S-2266
(3R,9S)-megastigman-5-en-3,9-diol 3-O-[alpha-L-arabinofuranosyl-(1->6)]-beta-D-glucopyranoside
11-O-acetyl-12-O-isovaleroyl-17beta-marsdenin|8-hydroxydrevogenin A
(1R,2E,4S,5R,6S,7E,10S,11S,12R)-5,6,10,18-tetraacetoxy-2,7-dolabelladiene|5,6,10,18-Tetraacetoxy-2,7-dolabelladiene
6alpha-O-(6-O-acetyl-beta-D-glucopyranosyl)-15,16-epoxycleroda-3,13(16),14-triene|salvigreside D
6beta-cinnamoyloxy-7beta-acetoxyvouacapen-5alpha-ol
(20S,22R,24S,25R)-5alpha,6beta,14alpha,17beta,20-pentahydroxy-1-oxowitha-2-en-22,26-olide|24,25-dihydrowithanolide S
7-megastigmen-3-ol-9-one 3-O-alpha-L-arabinofuranosyl-(1?6)-beta-D-glucopyranoside
3beta,4beta,5alpha,6beta,27-pentahydroxy-1-oxo-with-24-enolide
digitoxigenin-3-O-beta-d-xyloside|digitoxigenyl beta-D-xyloside
(2R,9R)-megastigman-5-en-2,9-diol 9-O-alpha-L-arabinopyranosyl(1->6)-beta-D-glucopyranoside|foliasalacioside I
14-O-alpha-L-rhamnopyranosyl-(2E,4E,7R,8E,10E,12E,14R)-7,9,13,17-tetramethyl-7,14-dihydroxy-2,4,8,10,12,16-octadecahexaenoic acid
Asn Val Phe Lys
Phe Val Ile Glu
Asn Phe Ala Arg
C30H38N2O5_(1E)-6-Hydroxy-12-(1H-indol-3-ylmethyl)-7-methoxy-4,13,13a-trimethyl-5,6,7,8,12,12a,13,13a,14a,14b-decahydro-3H-cycloundeca[d]oxireno[f]isoindole-9,10(4H,11H)-dione
C24H42O11_beta-D-Glucopyranoside, (1S,4R,5R)-4-[(1E,3R)-3-hydroxy-1-buten-1-yl]-3,3,5-trimethylcyclohexyl 6-O-[(2R,3R,4R)-tetrahydro-3,4-dihydroxy-4-(hydroxymethyl)-2-furanyl]
Ala Phe Asn Arg
Ala Phe Arg Asn
Ala Asn Phe Arg
Ala Asn Arg Phe
Ala Arg Phe Asn
Ala Arg Asn Phe
Cys Lys Arg Thr
Cys Lys Thr Arg
Cys Arg Lys Thr
Cys Arg Thr Lys
Cys Thr Lys Arg
Cys Thr Arg Lys
Asp Phe Ile Ile
Asp Phe Ile Leu
Asp Phe Leu Ile
Asp Phe Leu Leu
Asp Ile Phe Ile
Asp Ile Phe Leu
Asp Ile Ile Phe
Asp Ile Leu Phe
Asp Leu Phe Ile
Asp Leu Phe Leu
Asp Leu Ile Phe
Asp Leu Leu Phe
Glu Phe Ile Val
Glu Phe Leu Val
Glu Phe Val Ile
Glu Phe Val Leu
Glu Ile Phe Val
Glu Ile Val Phe
Glu Leu Phe Val
Glu Leu Val Phe
Glu Val Phe Ile
Glu Val Phe Leu
Glu Val Ile Phe
Glu Val Leu Phe
Phe Ala Asn Arg
Phe Ala Arg Asn
Phe Asp Ile Ile
Phe Asp Ile Leu
Phe Asp Leu Ile
Phe Asp Leu Leu
Phe Glu Ile Val
Phe Glu Leu Val
Phe Glu Val Ile
Phe Glu Val Leu
Phe Gly Lys Arg
Phe Gly Gln Arg
Phe Gly Arg Lys
Phe Gly Arg Gln
Phe Ile Asp Ile
Phe Ile Asp Leu
Phe Ile Glu Val
Phe Ile Ile Asp
Phe Ile Leu Asp
Phe Ile Met Pro
Phe Ile Pro Met
Phe Ile Val Glu
Phe Lys Gly Arg
Phe Lys Asn Val
Phe Lys Arg Gly
Phe Lys Val Asn
Phe Leu Asp Ile
Phe Leu Asp Leu
Phe Leu Glu Val
Phe Leu Ile Asp
Phe Leu Leu Asp
Phe Leu Met Pro
Phe Leu Pro Met
Phe Leu Val Glu
Phe Met Ile Pro
Phe Met Leu Pro
Phe Met Pro Ile
Phe Met Pro Leu
Phe Asn Ala Arg
Phe Asn Lys Val
Phe Asn Arg Ala
Phe Asn Val Lys
Phe Pro Ile Met
Phe Pro Leu Met
Phe Pro Met Ile
Phe Pro Met Leu
Phe Gln Gly Arg
Phe Gln Arg Gly
Phe Arg Ala Asn
Phe Arg Gly Lys
Phe Arg Gly Gln
Phe Arg Lys Gly
Phe Arg Asn Ala
Phe Arg Gln Gly
Phe Val Glu Ile
Phe Val Glu Leu
Phe Val Lys Asn
Phe Val Leu Glu
Phe Val Asn Lys
Gly Phe Lys Arg
Gly Phe Gln Arg
Gly Phe Arg Lys
Gly Phe Arg Gln
Gly Lys Phe Arg
Gly Lys Arg Phe
Gly Gln Phe Arg
Gly Gln Arg Phe
Gly Arg Phe Lys
Gly Arg Phe Gln
Gly Arg Lys Phe
Gly Arg Gln Phe
His His Ile Thr
His His Leu Thr
His His Thr Ile
His His Thr Leu
His Ile His Thr
His Ile Thr His
His Leu His Thr
His Leu Thr His
His Thr His Ile
His Thr His Leu
His Thr Ile His
His Thr Leu His
Ile Asp Phe Ile
Ile Asp Phe Leu
Ile Asp Ile Phe
Ile Asp Leu Phe
Ile Glu Phe Val
Ile Glu Val Phe
Ile Phe Asp Ile
Ile Phe Asp Leu
Ile Phe Glu Val
Ile Phe Ile Asp
Ile Phe Leu Asp
Ile Phe Met Pro
Ile Phe Val Glu
Ile His His Thr
Ile His Thr His
Ile Ile Asp Phe
Ile Ile Phe Asp
Ile Ile Met Met
Ile Leu Asp Phe
Ile Leu Phe Asp
Ile Leu Met Met
Ile Met Ile Met
Ile Met Leu Met
Ile Met Met Ile
Ile Met Met Leu
Ile Pro Phe Met
Ile Pro Met Phe
Ile Thr His His
Ile Val Glu Phe
Ile Val Phe Glu
Lys Cys Arg Thr
Lys Cys Thr Arg
Lys Phe Gly Arg
Lys Phe Asn Val
Lys Phe Arg Gly
Lys Phe Val Asn
Lys Gly Phe Arg
Lys Gly Arg Phe
Lys Lys Met Thr
Lys Lys Thr Met
Lys Met Lys Thr
Lys Met Thr Lys
Lys Asn Phe Val
Lys Asn Val Phe
Lys Arg Cys Thr
Lys Arg Phe Gly
Lys Arg Gly Phe
Lys Arg Thr Cys
Lys Thr Cys Arg
Lys Thr Lys Met
Lys Thr Met Lys
Lys Thr Arg Cys
Lys Val Phe Asn
Lys Val Asn Phe
Leu Asp Phe Ile
Leu Asp Phe Leu
Leu Asp Ile Phe
Leu Asp Leu Phe
Leu Glu Phe Val
Leu Glu Val Phe
Leu Phe Asp Ile
Leu Phe Asp Leu
Leu Phe Glu Val
Leu Phe Ile Asp
Leu Phe Leu Asp
Leu Phe Met Pro
Leu Phe Pro Met
Leu Phe Val Glu
Leu His His Thr
Leu His Thr His
Leu Ile Asp Phe
Leu Ile Phe Asp
Leu Ile Met Met
Leu Leu Asp Phe
Leu Leu Phe Asp
Leu Leu Met Met
Leu Met Phe Pro
Leu Met Ile Met
Leu Met Leu Met
Leu Met Met Ile
Leu Met Met Leu
Leu Met Pro Phe
Leu Pro Phe Met
Leu Pro Met Phe
Leu Thr His His
Leu Val Glu Phe
Leu Val Phe Glu
Met Phe Ile Pro
Met Phe Leu Pro
Met Phe Pro Ile
Met Phe Pro Leu
Met Ile Phe Pro
Met Ile Ile Met
Met Ile Leu Met
Met Ile Met Ile
Met Ile Met Leu
Met Ile Pro Phe
Met Lys Lys Thr
Met Lys Thr Lys
Met Leu Phe Pro
Met Leu Ile Met
Met Leu Leu Met
Met Leu Met Ile
Met Leu Met Leu
Met Leu Pro Phe
Met Met Ile Ile
Met Met Ile Leu
Met Met Leu Ile
Met Met Leu Leu
Met Pro Phe Ile
Met Pro Phe Leu
Met Pro Ile Phe
Met Pro Leu Phe
Met Thr Lys Lys
Asn Ala Phe Arg
Asn Ala Arg Phe
Asn Phe Lys Val
Asn Phe Arg Ala
Asn Phe Val Lys
Asn Lys Phe Val
Asn Lys Val Phe
Asn Arg Ala Phe
Asn Arg Phe Ala
Asn Val Lys Phe
Pro Phe Ile Met
Pro Phe Leu Met
Pro Phe Met Ile
Pro Phe Met Leu
Pro Ile Phe Met
Pro Ile Met Phe
Pro Leu Phe Met
Pro Leu Met Phe
Pro Met Phe Ile
Pro Met Phe Leu
Pro Met Ile Phe
Pro Met Leu Phe
Gln Phe Gly Arg
Gln Phe Arg Gly
Gln Gly Phe Arg
Gln Gly Arg Phe
Gln Arg Phe Gly
Gln Arg Gly Phe
Arg Ala Phe Asn
Arg Ala Asn Phe
Arg Cys Lys Thr
Arg Cys Thr Lys
Arg Phe Ala Asn
Arg Phe Gly Lys
Arg Phe Gly Gln
Arg Phe Lys Gly
Arg Phe Asn Ala
Arg Phe Gln Gly
Arg Gly Phe Lys
Arg Gly Phe Gln
Arg Gly Lys Phe
Arg Gly Gln Phe
Arg Lys Cys Thr
Arg Lys Phe Gly
Arg Lys Gly Phe
Arg Lys Thr Cys
Arg Asn Ala Phe
Arg Asn Phe Ala
Arg Gln Phe Gly
Arg Gln Gly Phe
Arg Thr Cys Lys
Arg Thr Lys Cys
Thr Cys Lys Arg
Thr Cys Arg Lys
Thr His His Ile
Thr His His Leu
Thr His Ile His
Thr His Leu His
Thr Ile His His
Thr Lys Cys Arg
Thr Lys Lys Met
Thr Lys Met Lys
Thr Lys Arg Cys
Thr Leu His His
Thr Met Lys Lys
Thr Arg Cys Lys
Thr Arg Lys Cys
Val Glu Phe Ile
Val Glu Phe Leu
Val Glu Ile Phe
Val Glu Leu Phe
Val Phe Glu Ile
Val Phe Glu Leu
Val Phe Ile Glu
Val Phe Lys Asn
Val Phe Leu Glu
Val Phe Asn Lys
Val Ile Glu Phe
Val Ile Phe Glu
Val Lys Phe Asn
Val Lys Asn Phe
Val Leu Glu Phe
Val Leu Phe Glu
Val Asn Phe Lys
Val Asn Lys Phe
(5Z,7E,22E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),22-cholestatetraene-3,25-diol
Ixabepilone
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide
(3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside]
4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside]
14-O-(alpha-L-rhamnopyranosyl)-7S,14R-dihydroxy-7,9,13,17-tetramethyl-2E,4E,8E,10E,12E,16E-octadecahexaenoic acid
(E)-12-((1H-indol-3-yl)methyl)-6-hydroxy-7-methoxy-4,13,13a-trimethyl-3,5,6,7,8,11,12,12a,13,13a,14a,14b-dodecahydro-9H-cycloundeca[d]oxireno[2,3-f]isoindole-9,10(4H)-dione
(22E)-26,26,26,27,27,27-hexafluoro-25-hydroxy-22,23-didehydrovitamin D3
(R)-5-(2-(benzyl(4-phenylbutan-2-yl)amino)acetyl)-2-(benzyloxy)benzamide
5-(di-tert-Butylphosphino)-1,3,5-triphenyl-1h-[1,4]bipyrazole
Bemcentinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Abemaciclib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
1-Hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3-phosphate
(1R)-1-(hydroxymethyl)-7-methoxy-2-[(3-methoxyphenyl)methyl]-N-propyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1S)-1-(hydroxymethyl)-7-methoxy-2-[(3-methoxyphenyl)methyl]-N-propyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
1-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-(2-methyl-4-thiazolyl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
2-[(1r,3ar,6r,7r,8r,12s,12as)-7,8,12-tris(acetyloxy)-3a,6,10-trimethyl-1h,2h,3h,6h,7h,8h,11h,12h,12ah-cyclopenta[11]annulen-1-yl]propan-2-yl acetate
(2e,4e,7s,8e,10e,12e,14r)-7-hydroxy-7,9,13,17-tetramethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}octadeca-2,4,8,10,12,16-hexaenoic acid
(2r,3r,5r,6r,8s,9s,10r,11r)-8,10-dihydroxy-3,5,9,11-tetramethyl-2-[(2r)-3-oxopentan-2-yl]-8-[(1s)-1-(3,5,6-trimethyl-4-oxopyran-2-yl)ethyl]-1,7-dioxaspiro[5.5]undecan-4-one
3-{[(1r,9r,13e)-13-ethylidene-5-hydroxy-11-methyl-6-azatricyclo[7.3.1.0²,⁷]trideca-2,4,6,10-tetraen-1-yl]amino}-3a,5-dihydroxy-6,8,8-trimethyl-3h,4h,5h,6h,6ah,7h,9h-azuleno[4,5-c]furan-1-one
(2s,3r,4s,5s,6r)-2-{[(1r)-4-[(3r)-3-hydroxybutyl]-3,5,5-trimethylcyclohex-3-en-1-yl]oxy}-6-({[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxane-3,4,5-triol
6-(1-{3a,5,5a-trihydroxy-9a,11a-dimethyl-9-oxo-dodecahydrocyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
(2r,3s,4s,5r,6s)-2-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[(2r)-4-[(1s)-1-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]butan-2-yl]oxy}oxane-3,4,5-triol
(6r)-6-[(1r)-1-[(1s,3ar,3br,5r,5ar,9ar,9br,11ar)-3a,5,5a-trihydroxy-9a,11a-dimethyl-9-oxo-dodecahydrocyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
15-(acetyloxy)-2-[2-(acetyloxy)ethylidene]-10-[(acetyloxy)methyl]-6,14-dimethylpentadeca-5,9,13-trien-1-yl acetate
2-({[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[4-(4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl)butan-2-yl]oxy}oxane-3,4,5-triol
(2r,3s,4s,5r,6r)-2-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[(1r)-4-[(3s)-3-hydroxybutyl]-3,5,5-trimethylcyclohex-3-en-1-yl]oxy}oxane-3,4,5-triol
(5s,7r,8r,10r,11r,12r,15r,16s,18z,25s)-11-acetyl-2,20-dihydroxy-10,26-dimethyl-21,26-diazapentacyclo[23.2.1.0⁵,¹⁶.0⁷,¹⁵.0⁸,¹²]octacosa-1,3,13,18,20-pentaene-27,28-dione
(2r,3r,4s,5r,6r)-2-({[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[(2r)-4-[(4s)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]butan-2-yl]oxy}oxane-3,4,5-triol
8,10-dihydroxy-3,5,9,11-tetramethyl-2-(3-oxopentan-2-yl)-8-[1-(3,5,6-trimethyl-4-oxopyran-2-yl)ethyl]-1,7-dioxaspiro[5.5]undecan-4-one
(2r,3r,4s,5s,6r)-2-{[(1s)-4-[(3r)-3-hydroxybutyl]-3,5,5-trimethylcyclohex-3-en-1-yl]oxy}-6-({[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxane-3,4,5-triol
(20r,22r)-5α,6β,14α,20,27-pentahydroxy-1-oxowitha-24-enolide
{"Ingredient_id": "HBIN003440","Ingredient_name": "(20r,22r)-5\u03b1,6\u03b2,14\u03b1,20,27-pentahydroxy-1-oxowitha-24-enolide","Alias": "NA","Ingredient_formula": "C28H42O8","Ingredient_Smile": "CC1=C(C(=O)OC(C1)C(C)(C2CCC3(C2(CCC4C3CC(C5(C4(C(=O)CCC5)C)O)O)C)O)O)CO","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16845","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(3r,9s)-megastigman-5-en-3,9-diol-3-o-[α-l-arabinofuranosyl-(1→6)]-β-d-glucopyranoside
{"Ingredient_id": "HBIN009576","Ingredient_name": "(3r,9s)-megastigman-5-en-3,9-diol-3-o-[\u03b1-l-arabinofuranosyl-(1\u21926)]-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C24H42O11","Ingredient_Smile": "CC1=C(C(CC(C1)OC2C(C(C(C(O2)COC3C(C(C(O3)CO)O)O)O)O)O)(C)C)CCC(C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "13635","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}